Amendments to the Claims

1. (Original)   An epidermal growth factor receptor (EGFR)-derived peptide or mutant peptide thereof which is capable of inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

2. (Original)   The peptide of Claim 1, wherein the EGFR-derived peptide consists of at least 8 consecutive amino acid residues derived from the amino acid sequence of $EGFR_{800-809}$, $EGFR_{124-132}$, $EGFR_{54-62}$, $EGFR_{479-488}$ or $EGFR_{1138-1147}$.

3. (Original)   A polypeptide consisting of 8 to 50 amino acid residues, which comprises the peptide of Claim 1 or 2 and is capable of inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

4. (Currently amended)   A nucleic acid molecule encoding the peptide of Claim 1 or 2 ~~or the polypeptide of Claim 3~~.

5. (Original)   A vector comprising the nucleic acid molecule of Claim 4.

6. (Currently amended)   A pharmaceutical composition comprising the peptide of Claim 1 or 2, ~~the polypeptide of Claim 3, or the nucleic acid molecule of Claim 4,~~ for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

7. (Original)   The pharmaceutical composition of Claim 6, which is used as a cancer vaccine.

8. (Currently amended)   An EGFR-reactive cytotoxic T lymphocyte which recognizes a complex between the peptide of Claim 1 or 2 ~~or the polypeptide of Claim 3~~ and an HLA molecule.

3

9. (Currently amended)   A method for inducing an EGFR-reactive cytotoxic T lymphocyte using the peptide of Claim 1 or 2 ~~or the polypeptide of Claim 3~~.

10. (Currently amended)   An antibody which specifically recognizes the peptide of Claim 1 or 2 ~~or the polypeptide of Claim 3~~.

11. (New)   A nucleic acid molecule encoding the polypeptide of Claim 3.

12. (New)   A vector comprising the nucleic acid molecule of Claim 11.

13. (New)   A pharmaceutical composition comprising the peptide of Claim 3, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

14. (New)   The pharmaceutical composition of Claim 13, which is used as a cancer vaccine.

15. (New)   A pharmaceutical composition comprising the nucleic acid molecule of Claim 4, for inducing a cytotoxic T lymphocyte and an antibody specific for said peptide.

16. (New)   The pharmaceutical composition of Claim 15, which is used as a cancer vaccine.

17. (New) An EGFR-reactive cytotoxic T lymphocyte which recognizes a complex between the polypeptide of Claim 3 and an HLA molecule.

18. (New) A method for inducing an EGFR-reactive cytotoxic T lymphocyte using the polypeptide of Claim 3.

19. (New)   An antibody which specifically recognizes the polypeptide of Claim 3.